Merck Bolsters Oncology Pipeline with $2.13 Billion SciBrunch Licensing Deal for KRAS G12D Inhibitor
In a significant move to reshape its oncology portfolio ahead of impending patent cliffs, Merck & Co. has secured exclusive...
In a significant move to reshape its oncology portfolio ahead of impending patent cliffs, Merck & Co. has secured exclusive...